Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5871-5880 Newer>

BusinessWeek September 1, 2009 Catherine Arnst	Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight.
The Motley Fool September 2, 2009 Chris Jones	China Medical, Heal Thyself When will China Medical stop letting setbacks get in its way?
The Motley Fool September 2, 2009 Brian Orelli	Pfizer's Paying $2.3 Billion Again? Oh, Wait, Never Mind. There are 17 articles on the Yahoo! Finance ticker feed announcing or discussing the $2.3 billion settlement Pfizer made with the Department of Justice.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
The Motley Fool September 2, 2009 Robert Steyer	Pharma's Next Home Run Drug Could Be 4 Singles Instead With mixed success in the women's health field, drugmakers try to turn a single compound into a treatment for several diseases and conditions.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool August 31, 2009 Brian Orelli	Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way.
The Motley Fool August 31, 2009 Brian Orelli	Good Luck, Genzyme -- You'll Need It The drugmaker faces an FDA advisory-panel showdown regarding its leukemia drug Clolar.
The Motley Fool August 31, 2009 Brian Orelli	Stop Buying the Rumor Last week, two pharma companies that were the subject of buyout rumors saw their stocks rise dramatically, only to fall as the buyouts failed to pan out.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
<Older 5871-5880 Newer> Return to current articles.